Linked Data API

Show Search Form

Search Results

1007480
star this property registered interest false more like this
star this property date remove filter
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading NHS: Counter-terrorism more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what plans they have to implement the Prevent Strategy within the NHS as a safeguarding measure to protect those with care and support needs. more like this
star this property tabling member printed
Baroness Afshar more like this
star this property uin HL11484 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2018-11-28more like thismore than 2018-11-28
star this property answer text <p>The Department is committed to ensuring that the National Health Service fully embeds the Prevent Statutory Duty of 2015 within its safeguarding responsibilities.</p><p>Great strides have been taken to embed Prevent within the health sector to date. For example, since the Prevent Duty made training mandatory over 830,000 NHS staff have received Basic Prevent Awareness training and over 470,000 have attended advanced training.</p><p>The Department is committed to engaging with relevant professional bodies and ensure that further opportunities to develop bespoke training for health professionals are undertaken.</p> more like this
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
less than 2018-11-28T14:50:55.367Zmore like thismore than 2018-11-28T14:50:55.367Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
3847
unstar this property label Biography information for Baroness Afshar more like this
1007497
star this property registered interest false more like this
star this property date remove filter
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Palliative Care more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assessment they have made of the geographical differences in the quality and provision of (1) specialist, and (2) generalist palliative care services across England. more like this
star this property tabling member printed
Baroness Finlay of Llandaff more like this
star this property uin HL11498 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2018-11-28more like thismore than 2018-11-28
star this property answer text <p>As with the vast majority of NHS services, the funding and commissioning of palliative and end of life care is a local matter, over which individual National Health Service commissioners have responsibility. Local commissioners are best placed to understand the needs of local populations and commission services to meet those needs accordingly.</p><p>In October 2018 Public Health England, in partnership with NHS RightCare, published the first <em>Atlas of variation for palliative and end of life care in England</em> which can be used as a tool by commissioners to better understand the needs of their local population and reduce unwarranted variation. A copy of the Atlas has been placed in the Library due to its size.</p> more like this
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
less than 2018-11-28T14:48:01.297Zmore like thismore than 2018-11-28T14:48:01.297Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
3609
unstar this property label Biography information for Baroness Finlay of Llandaff more like this
1007498
star this property registered interest false more like this
star this property date remove filter
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Flour: Folic Acid more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assessment they have made of research into the impact of folic acid flour fortification on the development of neural tube defects, such as spina bifida. more like this
star this property tabling member printed
Baroness Finlay of Llandaff more like this
star this property uin HL11499 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2018-11-28more like thismore than 2018-11-28
star this property answer text <p>The Scientific Advisory Committee on Nutrition (SACN) published risk assessments on folic acid in 2006, 2009 and 2017. The SACN’s, <em>Update on Folic Acid</em> report published in 2017 reconfirmed that its previous recommendation, in 2006 and 2009, for mandatory folic acid fortification to improve the folate status of women most at risk of neural tube defect-affected pregnancies remains unchanged.</p><p>The report stated that the evidence published since the SACN’s previous reports in 2006 and 2009, on potential adverse effects of folic acid, does not provide a substantial basis for changing this recommendation.</p><p>A copy of the SACN’s <em>Update on Folic Acid</em>, 2017, is attached.</p><p>In October the Government announced it will be launching consultation on adding folic acid to flour. This consultation will explore the issues around this complex area and will allow Ministers to take an informed decision on whether to introduce mandatory fortification of flour with folic acid. The timeline for the consultation will be announced shortly.</p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
less than 2018-11-28T13:58:54.5Zmore like thismore than 2018-11-28T13:58:54.5Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property attachment
1
unstar this property file name SACN_Update_on_folic_acid_2017.pdf more like this
star this property title SACN_Update_on_folic_acid_2017 more like this
star this property tabling member
3609
unstar this property label Biography information for Baroness Finlay of Llandaff more like this
1007501
star this property registered interest false more like this
star this property date remove filter
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Cancer: Screening more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assessment they have made of (1) the economic importance of clinical trial recruitment, especially in cancer research, to the UK economy, and (2) the importance of timely molecular testing in modern cancer trial recruitment; and whether, as a result of any such assessment, NHS England will consider implementing national somatic gene testing in cancers with low survival rates to catalyse research. more like this
star this property tabling member printed
Lord Freyberg more like this
star this property uin HL11501 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2018-11-28more like thismore than 2018-11-28
star this property answer text <p>Clinical trial recruitment is important to the United Kingdom economy, especially in cancer research. For example, an independent report, commissioned by the National Institute for Health Research (NIHR) Clinical Research Network (CRN) and produced by KPMG’s Economics team, provided an assessment of the economic impact of the NIHR Clinical Research Network’s activities to support clinical research in the UK. The report estimated the gross value added and employment in the UK from CRN supported clinical research activity. It estimated that in the period April 2014 to March 2015 (financial year 2014/15) this activity generated a total of £2.4 billion gross value added and almost 39,500 jobs. Studies on cancer comprise a major part of CRN activity. A copy of <em>NIHR Clinical Research Network: Impact and Value Assessment</em> is attached.</p><p>A growing proportion of cancer trials supported by the NIHR involve molecular testing. One of the main purposes of the NIHR is to initiate studies speedily, and deliver them to time and target. Therefore timely molecular testing is important. This involves working with National Health Service pathology services to ensure that all essential steps are in place to deliver research studies.</p><p>The Chief Scientific Adviser has not made a specific assessment of the importance of molecular testing to drive cancer trial treatment. If a clinical trial that is to be delivered by the NIHR involves somatic gene testing that is not already in place, then the NHS will set up this new somatic gene testing as part of the delivery of the trial. Thus it is the nature of the research that drives clinical trial recruitment rather than the nature of the somatic gene testing that is in place.</p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN HL11502 more like this
star this property question first answered
less than 2018-11-28T14:50:06.697Zmore like thismore than 2018-11-28T14:50:06.697Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property attachment
1
unstar this property file name NIHR_CRN_Impact_and_Value_Assessment.pdf more like this
star this property title NIHR_CRN_Impact_and_Value_Assessment more like this
star this property tabling member
2593
unstar this property label Biography information for Lord Freyberg more like this
1007502
star this property registered interest false more like this
star this property date remove filter
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Cancer: Screening more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assessment the Chief Scientific Adviser has made of the importance of molecular testing to drive modern cancer trial recruitment, and of the introduction of such testing for which cancers offer the most value to the UK in terms of driving clinical trial recruitment. more like this
star this property tabling member printed
Lord Freyberg more like this
star this property uin HL11502 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2018-11-28more like thismore than 2018-11-28
star this property answer text <p>Clinical trial recruitment is important to the United Kingdom economy, especially in cancer research. For example, an independent report, commissioned by the National Institute for Health Research (NIHR) Clinical Research Network (CRN) and produced by KPMG’s Economics team, provided an assessment of the economic impact of the NIHR Clinical Research Network’s activities to support clinical research in the UK. The report estimated the gross value added and employment in the UK from CRN supported clinical research activity. It estimated that in the period April 2014 to March 2015 (financial year 2014/15) this activity generated a total of £2.4 billion gross value added and almost 39,500 jobs. Studies on cancer comprise a major part of CRN activity. A copy of <em>NIHR Clinical Research Network: Impact and Value Assessment</em> is attached.</p><p>A growing proportion of cancer trials supported by the NIHR involve molecular testing. One of the main purposes of the NIHR is to initiate studies speedily, and deliver them to time and target. Therefore timely molecular testing is important. This involves working with National Health Service pathology services to ensure that all essential steps are in place to deliver research studies.</p><p>The Chief Scientific Adviser has not made a specific assessment of the importance of molecular testing to drive cancer trial treatment. If a clinical trial that is to be delivered by the NIHR involves somatic gene testing that is not already in place, then the NHS will set up this new somatic gene testing as part of the delivery of the trial. Thus it is the nature of the research that drives clinical trial recruitment rather than the nature of the somatic gene testing that is in place.</p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN HL11501 more like this
star this property question first answered
less than 2018-11-28T14:50:06.647Zmore like thismore than 2018-11-28T14:50:06.647Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property attachment
1
unstar this property file name NIHR_CRN_Impact_and_Value_Assessment.pdf more like this
star this property title NIHR_CRN_Impact_and_Value_Assessment more like this
star this property tabling member
2593
unstar this property label Biography information for Lord Freyberg more like this
1007503
star this property registered interest false more like this
star this property date remove filter
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Cancer more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government how the UK's (1) one year, and (2) five year cancer survival rates compare to (a) France, (b) Germany, (c) Belgium, and (d) Sweden, as reported in international comparisons such as Eurocare-5; and what are the 20 cancers by incidence for which the difference in survival rates between the UK and other countries is greatest. more like this
star this property tabling member printed
Lord Freyberg more like this
star this property uin HL11503 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2018-11-28more like thismore than 2018-11-28
star this property answer text <p>The following table provides data on one-year and five-year relative survival by percentage for all cancer patients diagnosed 2000-07 in England, France, Germany, Belgium and Sweden; age-standardised.</p><p>One-year and five-year relative survival (%) for all cancer patients diagnosed 2000-2007 in England, France, Germany, Belgium and Sweden; age-standardised.</p><p> </p><table><tbody><tr><td><p> </p></td><td><p>One year</p></td><td><p>Five year</p></td></tr><tr><td><p>England</p></td><td><p>68.14%</p></td><td><p>50.20%</p></td></tr><tr><td><p>France</p></td><td><p>77.75%</p></td><td><p>58.62%</p></td></tr><tr><td><p>Germany</p></td><td><p>76.71%</p></td><td><p>59.09%</p></td></tr><tr><td><p>Belgium</p></td><td><p>78.90%</p></td><td><p>60.44%</p></td></tr><tr><td><p>Sweden</p></td><td><p>81.13%</p></td><td><p>64.75%</p></td></tr></tbody></table><p> </p><p>Tables showing one-year relative survival by percentage for all patients diagnosed with 20 cancers 2000-07 in England, France, Germany, Belgium and Sweden; age-standardised and five-year relative survival by percentage for all patients diagnosed with 20 cancers 2000-07 in England, France, Germany, Belgium and Sweden; age-standardised are attached due to the size of the data.</p><p>The 20 cancers listed in the attached table have the highest numbers of diagnoses in England and are ranked according to the number of diagnoses.</p><p>The source of this data is EUROCARE.</p><p>It should be noted that EUROCARE does not provide data for the United Kingdom as a whole. The tables contain information for England only.</p><p>EUROCARE provides full coverage of the populations of Sweden and England, but only provides 11.1-22.3% national coverage for France; 22.6% for Germany and 58.1% for Belgium.</p><p>Source: Rossi et al., The EUROCARE-5 study on cancer survival in Europe 1999-2007: Database, quality checks and statistical analytical methods European Journal of Cancer 2015; 51: 2104-19.</p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
less than 2018-11-28T14:51:55.973Zmore like thismore than 2018-11-28T14:51:55.973Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property attachment
1
unstar this property file name HL11503_attachment_formatted.docx more like this
star this property title HL11503_attachment_formatted more like this
star this property tabling member
2593
unstar this property label Biography information for Lord Freyberg more like this
1007513
star this property registered interest false more like this
star this property date remove filter
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Carers more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what measures will be included in the NHS Long Term Plan to ensure that unpaid carers are (1) identified, and (2) offered support. more like this
star this property tabling member printed
Baroness Pitkeathley more like this
star this property uin HL11511 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2018-11-28more like thismore than 2018-11-28
star this property answer text <p>The Government is committed to supporting carers to provide care as they would wish, and to do so in a way that supports their own health and wellbeing and other life chances.</p><p>The Long Term Plan is currently in development and is due to be published later this year. The content of the plan has yet to be determined, but it is anticipated that plan will acknowledge the important role played by unpaid carers.</p><p>In addition, we set out our commitments to supporting carers in the short-term through the <em>Carers Action Plan 2018-2020: Supporting carers today</em>, published in June. The Plan includes commitments from across Government and the National Health Service. For example, the NHS England and the Care Quality Commission are working together to develop quality standards for general practitioner surgeries to demonstrate how effective they are in identifying and supporting carers. A copy of the <em>Carers Action Plan</em> is attached. We recognise that there is still more to do and that is why the forthcoming Adult Social Care Green Paper will include a focus on how society supports carers as a vital part of a sustainable health and social care system so that they are properly valued, recognised and supported to provide care in a way that supports their own health and wellbeing.</p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
less than 2018-11-28T17:21:15.737Zmore like thismore than 2018-11-28T17:21:15.737Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property attachment
1
unstar this property file name Carers Action Plan PDF.pdf more like this
star this property title Carers Action Plan more like this
star this property tabling member
3179
unstar this property label Biography information for Baroness Pitkeathley more like this
1006976
star this property registered interest false more like this
star this property date remove filter
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Palliative Care: Children more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that all children with life-limiting conditions have access to an advance care plan, as recommended by the National Institute for Health and Care Excellence. more like this
star this property tabling member constituency Glasgow East more like this
star this property tabling member printed
David Linden more like this
star this property uin 191451 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2018-11-21more like thismore than 2018-11-21
star this property answer text <p>Local commissioners, who are responsible for delivering the majority of children’s palliative and end of life care, should take the National Institute of Health and Care Excellence guidance into account when planning services for local populations.</p><p> </p><p>To support implementation of the guidance NHS England commissioned Together for Short Lives, a leading children’s end of life care charity, to examine services across the country to identify best practice in implementation of the guidance, as well as barriers, through interviews with local NHS services. Together for Short Lives have now provided a suite of solutions to enable local areas to meet the needs of children at the end of life. More information about this work can be found at the following link:</p><p> </p><p><a href="http://www.togetherforshortlives.org.uk/changing-lives/supporting-care-professionals/introduction-childrens-palliative-care/nice-guidelines/" target="_blank">www.togetherforshortlives.org.uk/changing-lives/supporting-care-professionals/introduction-childrens-palliative-care/nice-guidelines/</a></p>
star this property answering member constituency Gosport more like this
star this property answering member printed Caroline Dinenage more like this
star this property question first answered
less than 2018-11-21T14:41:45.893Zmore like thismore than 2018-11-21T14:41:45.893Z
star this property answering member
4008
star this property label Biography information for Dame Caroline Dinenage more like this
star this property tabling member
4640
unstar this property label Biography information for David Linden more like this
1006994
star this property registered interest false more like this
star this property date remove filter
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading AAT Deficiency more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, if he take steps to make available intravenous alpha-1 augmentation therapy through the NHS to treat alpha-1. more like this
star this property tabling member constituency Birkenhead more like this
star this property tabling member printed
Frank Field more like this
star this property uin 191306 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2018-11-21more like thismore than 2018-11-21
star this property answer text <p>NHS England is engaging with the National Institute for Health and Care Excellence (NICE) on the Highly Specialised Technologies evaluation of human alpha1-proteinase inhibitor for treating emphysema in adults with documented severe alpha1 antitrypsin deficiency. NICE has not yet published final guidance and recently consulted on its draft guidance.</p><p> </p><p>NICE’s evaluation committee is due to meet again to consider its recommendations in spring next year. This is to enable the company that makes the alpha1-proteinase inhibitor to prepare and submit additional information for consideration by the committee. Once NICE guidance is received, NHS England will then consider the commissioning implications in consultation with the Specialised Respiratory Clinical Reference Group.</p> more like this
star this property answering member constituency Gosport more like this
star this property answering member printed Caroline Dinenage more like this
star this property question first answered
less than 2018-11-21T14:37:29.847Zmore like thismore than 2018-11-21T14:37:29.847Z
star this property answering member
4008
star this property label Biography information for Dame Caroline Dinenage more like this
star this property tabling member
478
unstar this property label Biography information for Lord Field of Birkenhead more like this
1006995
star this property registered interest false more like this
star this property date remove filter
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading AAT Deficiency more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, when he plans a NHS service for alpha-1 to improve patients' access to coordinated multi-disciplinary clinical expertise, which was approved by the Department's Prescribed Specialised Services Advisory Group in March 2016, to commence. more like this
star this property tabling member constituency Birkenhead more like this
star this property tabling member printed
Frank Field more like this
star this property uin 191307 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2018-11-21more like thismore than 2018-11-21
star this property answer text <p>The Specialised Respiratory Clinical Reference Group (CRG) is maintaining an oversight of the need to develop a service specification and selection of providers to offer specialised expertise and management advice for patients diagnosed with alpha1 antitrypsin deficiency (AATD).</p><p> </p><p>The CRG has recommended that NHS England wait until it is clear on the outcome of the National Institute for Health and Care Excellence (NICE) Highly Specialised Technologies evaluation of human alpha1-proteinase inhibitor for treating emphysema in adults with documented severe AATD [ID856] until this development is taken forward.</p><p> </p><p>NICE has not yet published final guidance and recently consulted on its draft guidance. NICE’s evaluation committee is due to meet again to consider its recommendations in spring next year. This is to enable the company that makes the alpha1-proteinase inhibitor to prepare and submit additional information for consideration by the committee.</p> more like this
star this property answering member constituency Gosport more like this
star this property answering member printed Caroline Dinenage more like this
star this property question first answered
less than 2018-11-21T14:39:19.47Zmore like thismore than 2018-11-21T14:39:19.47Z
star this property answering member
4008
star this property label Biography information for Dame Caroline Dinenage more like this
star this property tabling member
478
unstar this property label Biography information for Lord Field of Birkenhead more like this